Format

Send to

Choose Destination
FEBS Lett. 2016 Jun;590(11):1651-62. doi: 10.1002/1873-3468.12196. Epub 2016 May 27.

Identification of novel bile acids as biomarkers for the early diagnosis of Niemann-Pick C disease.

Author information

1
Centre for Translational Omics, Genetics and Genomic Medicine Programme, UCL Institute of Child Health, London, UK.
2
Metabolic Medicine, Great Ormond Street Children's Hospital, London, UK.
3
Department of Pharmacology, University of Oxford, UK.
4
Program in Developmental Endocrinology and Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA.
5
Department of Pharmaceutical Sciences, Tohoku University Hospital, Japan.
6
College of Humanities and Sciences, Nihon University, Tokyo, Japan.

Abstract

This article describes a rapid UPLC-MS/MS method to quantitate novel bile acids in biological fluids and the evaluation of their diagnostic potential in Niemann-Pick C (NPC). Two new compounds, NPCBA1 (3β-hydroxy,7β-N-acetylglucosaminyl-5-cholenoic acid) and NPCBA2 (probably 3β,5α,6β-trihydroxycholanoyl-glycine), were observed to accumulate preferentially in NPC patients: median plasma concentrations of NPCBA1 and NPCBA2 were 40- and 10-fold higher in patients than in controls. However, NPCBA1 concentrations were normal in some patients because they carried a common mutation inactivating the GlcNAc transferase required for the synthesis of this bile acid. NPCBA2, not containing a GlcNAc moiety, is thus a better NPC biomarker.

KEYWORDS:

Biomarkers; GlcNAc transferase; Niemann-Pick C; UPLC-MS/MS; bile acids; screening

PMID:
27139891
PMCID:
PMC5089630
DOI:
10.1002/1873-3468.12196
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center